Merck Surpasses Q4 Earnings Expectations, But Stock Drops in Pre-Market Trading Due to Tepid 2025 Outlook
Merck & Co. (MRK) recently unveiled its fourth quarter and full-year earnings report, meeting Wall Street expectations but failing to excite investors in the pre-market trading session. The company’s stock plummeted over 8% following the … Read more